Structure–activity relationship analysis in a series of 3-(5-((2-oxoindolin-3-ylidene) methyl) furan-2-yl) amides identified compound 13, a pan-Pim kinases inhibitor with excellent biochemical potency and kinase selectivity. Compound 13 exhibited in vitro synergy with chemotherapeutics and robust in vivo efficacy in two Pim kinases driven tumor models.